摘要
目的:观察阿托伐他汀对老年2型糖尿病合并非酒精性脂肪肝患者降脂疗效和安全性。方法:选择老年2型糖尿合并非酒精性脂肪肝患者39例,每晚睡前服用阿托伐他汀20 mg,疗程为6个月。治疗前及治疗后3、6个月分别测定血总胆固醇(TC),三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白(LDL-C)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、血糖、肌酐(Cr)。结果:阿托伐他汀治疗6个月后,患者TC、TG、LDL-C均显著降低[(5.03±0.74)mmol/L至(3.14±0.43)mmol/L,(1.91±0.40)mmol/L至(1.21±0.56)mmol/L,(3.01±0.78)mmol/L至(1.64±0.31)mmol/L],前后差异均有高度统计学意义(均P<0.01)。治疗期间,ALT、AST、Cr未出现明显变化。结论:阿托伐他汀对老年2型糖尿病合并非酒精性脂肪肝患者有明显降脂效果,不良反应小。
Objective:To observe effect of Atorvastatin on lowering blood lipid in patients with type 2 diabetic mellitus plus non-alcoholic fatty liver.Methods:39 cases of old patients were selected and given Atorvastatin 20 mg every night for 6 months.The levels of total cholesterol(TC),triglycerides(TG),high density lipoprotein cholesterol(HDL-C),low density lipoprotein cholesterol(LDL-C),serum alanine(Cr) were examined before and 3,6 months after the treatment.Results:TC [(5.03±0.74) mmol/L vs(3.14±0.43)mmol/L],TG [(1.91±0.40) mmol/L vs(1.21±0.56) mmol/L],LDL-C [(3.01±0.78) mmol/L vs(1.64±0.31) mmol/L] were significantly decreased 6 months after the treatment(P〈0.01).No significant changes were observed in ALT,AST and Cr.Conclusion:Atorvastatin may significantly decrease the level of blood lipid with little adverse effect in elderly patients with type 2 diabetic mellitus plus non-alcoholic fatty liver.
出处
《中国医药导报》
CAS
2011年第30期72-74,共3页
China Medical Herald
关键词
降血脂药
2型糖尿病
非酒精性脂肪肝
Antilipemic agents; Type 2 diabetes mellitus; Non-alcoholic fatty liver